Its CD19CART component expanded on engaging CD19 T-cells, which activate GCCCART directed against mCRC that express GCC; an objective response occurred in 40% of patients with mCRC, and GCC19CART was well tolerated, with diarrhea, an on-target effect, as its principal toxic effect. The gene discussed is CD19; the disease is goblet cell carcinoma.